Scorpius Holdings, Inc. (SCPX)
USD 0.12
(-8.93%)
USD 0.12
(-8.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.85 Million USD | 1348.29% |
| 2022 | 956.79 Thousand USD | 115.62% |
| 2021 | -6.12 Million USD | 32.55% |
| 2020 | -9.08 Million USD | -27.72% |
| 2019 | -7.11 Million USD | 67.9% |
| 2018 | -22.15 Million USD | -126.92% |
| 2017 | -9.76 Million USD | -24.49% |
| 2016 | -7.84 Million USD | -534.26% |
| 2015 | 1.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 14.11 Million USD | 1.84% |
| 2024 Q2 | 14.39 Million USD | 2.03% |
| 2023 Q1 | 1.27 Million USD | 32.94% |
| 2023 Q4 | 13.85 Million USD | 23.66% |
| 2023 Q3 | 11.2 Million USD | 107.23% |
| 2023 FY | 13.85 Million USD | 1348.29% |
| 2023 Q2 | 5.4 Million USD | 325.13% |
| 2022 Q4 | 956.79 Thousand USD | 118.88% |
| 2022 Q3 | -5.06 Million USD | 36.32% |
| 2022 Q2 | -7.95 Million USD | 36.43% |
| 2022 Q1 | -12.51 Million USD | -104.35% |
| 2022 FY | 956.79 Thousand USD | 115.62% |
| 2021 Q3 | -5.81 Million USD | 70.77% |
| 2021 FY | -6.12 Million USD | 32.55% |
| 2021 Q2 | -19.9 Million USD | 32.29% |
| 2021 Q4 | -6.12 Million USD | -5.31% |
| 2021 Q1 | -29.4 Million USD | 0.0% |
| 2020 FY | -9.08 Million USD | -27.72% |
| 2019 FY | -7.11 Million USD | 67.9% |
| 2018 FY | -22.15 Million USD | -126.92% |
| 2017 FY | -9.76 Million USD | -24.49% |
| 2016 FY | -7.84 Million USD | -534.26% |
| 2015 FY | 1.8 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 380.282% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 463.227% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 87.031% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 118.584% |
| Azitra, Inc. | -910.04 Thousand USD | 1622.69% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 426.973% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | -1082.051% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | -167.151% |
| CEL-SCI Corporation | 9.42 Million USD | -47.009% |
| iBio, Inc. | -9.75 Million USD | 242.124% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 142.65% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 293.787% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | 1181.742% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -3060.522% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | 3653.107% |
| NanoViricides, Inc. | -4.79 Million USD | 388.824% |
| Oragenics, Inc. | -3.17 Million USD | 537.023% |
| BiomX Inc. | -772 Thousand USD | 1894.963% |
| BiomX Inc. | -772 Thousand USD | 1894.963% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | -423.503% |
| Palatin Technologies, Inc. | -8.93 Million USD | 255.052% |
| Theriva Biologics, Inc. | -21.02 Million USD | 165.914% |